A new study published in Science Advances explains how an enzyme called SMYD3 may play a role in the advancement of prostate cancer to a more hazardous and aggressive stage.
Professor Nicholas Tonks' laboratory identified an antibody that can suppress an enzyme that may aid in the spread of some breast tumours. With more research, the antibody may be able to give a feasible therapeutic treatment for the same breast cancers.
An antibody developed in the lab of Cold Spring Harbour Laboratory Professor Nicholas Tonks can inhibit an enzyme that may aid in the spread of some breast tumours. With additional research, the antibody could provide a viable therapeutic treatment for the same breast tumours.
Plant biologists at the DOE's Brookhaven National Laboratory in the United States have developed enzymes to change grass plants so that their biomass can be turned more efficiently into biofuels and other bioproducts.
Scientists at The University of Toledo have shown that engineered bacteria can lower blood pressure and the finding opens avenues to harness the body's own microbiome to treat hypertension
Resistant starch is a nondigestible fibre that ferments in the large intestine and has previously been found to boost metabolism in animal tests.
A 4-month randomised controlled experiment in persons with non-alcoholic fatty liver disease (NAFLD) found that regularly eating resistant starch
A novel method of optimising plant enzymes through bioengineering has expanded the understanding of how plant material can be transformed into biofuels, biochemicals, and other high-value goods.
Resistant starch is a nondigestible fibre that ferments in the large intestine, and it has previously been demonstrated in animal experiments to have a favourable effect on metabolism. A 4-month randomised controlled experiment in persons with non-alcoholic fatty liver disease (NAFLD) has fo
Bacteria utilise a number of strategies to combat the treatments meant to kill them. One of the most prevalent of these weapons is ribosome-modifying enzymes. These enzymes are becoming increasingly common, appearing in clinical samples from bacteria with varying drug resistances all over th
Group A streptococci are widespread bacteria that can cause strep throat and impetigo, among other problems. However, if the bacteria become invasive, the situation might quickly deteriorate. In this situation, the name may change to killer bacteria or flesh-eating bacteria, and it can cause
Bacteria use a variety of methods to fight off the medications designed to destroy them. Ribosome-modifying enzymes are one of these weapons that are most common and these enzymes are becoming more widespread